TY - JOUR
T1 - A structural basis for antibody-mediated neutralization of Nipah virus reveals a site of vulnerability at the fusion glycoprotein apex
AU - Avanzato, Victoria A.
AU - Oguntuyo, Kasopefoluwa Y.
AU - Escalera-Zamudio, Marina
AU - Gutierrez, Bernardo
AU - Golden, Michael
AU - Kosakovsky Pond, Sergei L.
AU - Pryce, Rhys
AU - Walter, Thomas S.
AU - Seow, Jeffrey
AU - Doores, Katie J.
AU - Pybus, Oliver G.
AU - Munster, Vincent J.
AU - Lee, Benhur
AU - Bowden, Thomas A.
N1 - Funding Information:
Biology Organization Long-Term Fellowship (ALTF376-2017). B.G. is supported by the 2017 Universities of Academic Excellence Scholarship Program of the Secretariat for Higher Education, Science, Technology and Innovation of the Republic of Ecuador (ARSEQ-BEC-003163-2017), and by Universidad San Francisco de Quito. M.G and O.G.P. are supported by the European Union’s Seventh Framework Programme (FP7/2007-2013)/European Research Council (614725-PATHPHYLODYN). S.L.K.P. is supported in part by NIH grants R01 GM093939 (NIH/National Institute of General Medical Sciences) and R01 AI134384 (NIH/National Institute of Allergy and Infectious Diseases). V.A.A. and V.J.M. are supported by the Division of Intramural research of the National Institute of Allergy and Infectious Diseases and through the Defense Advanced Research Planning Agency and Preeventing Emerging Pathogenic Threats program Cooperative Agreement D18AC00031.
Funding Information:
ACKNOWLEDGMENTS. We thank the staff of beamline i03 at the Diamond Light Source (mx19946) for assistance with data collection. This work was funded by Medical Research Council MR/L009528/1 and MR/S007555/1 (to T.A.B.), MR/N00065X/1 (to T.S.W.), and MR/N002091/1 (to T.A.B. and K.J.D.). T.A.B. and B.L. acknowledge funding from NIH Grant R01 AI123449 held with Alex Freiberg. The Wellcome Centre for Human Genetics is supported by Grant 203141/Z/16/Z. M.E.-Z. is supported by an European Molecular
Funding Information:
We thank the staff of beamline i03 at the Diamond Light Source (mx19946) for assistance with data collection. This work was funded by Medical Research Council MR/L009528/1 and MR/S007555/1 (to T.A.B.), MR/N00065X/1 (to T.S.W.), and MR/N002091/1 (to T.A.B. and K.J.D.). T.A.B. and B.L. acknowledge funding from NIH Grant R01 AI123449 held with Alex Freiberg. The Wellcome Centre for Human Genetics is supported by Grant 203141/Z/16/Z. M.E.-Z. is supported by an European Molecular Biology Organization Long-Term Fellowship (ALTF376-2017). B.G. is supported by the 2017 Universities of Academic Excellence Scholarship Program of the Secretariat for Higher Education, Science, Technology and Innovation of the Republic of Ecuador (ARSEQ-BEC-003163-2017), and by Universidad San Francisco de Quito. M.G and O.G.P. are supported by the European Union?s Seventh Framework Programme (FP7/2007-2013)/European Research Council (614725-PATHPHYLODYN). S.L.K.P. is supported in part by NIH grants R01 GM093939 (NIH/National Institute of General Medical Sciences) and R01 AI134384 (NIH/National Institute of Allergy and Infectious Diseases). V.A.A. and V.J.M. are supported by the Division of Intramural research of the National Institute of Allergy and Infectious Diseases and through the Defense Advanced Research Planning Agency and Preeventing Emerging Pathogenic Threats program Cooperative Agreement D18AC00031.
Publisher Copyright:
© 2019 National Academy of Sciences. All rights reserved.
PY - 2019/12/10
Y1 - 2019/12/10
N2 - Nipah virus (NiV) is a highly pathogenic paramyxovirus that causes frequent outbreaks of severe neurologic and respiratory disease in humans with high case fatality rates. The 2 glycoproteins displayed on the surface of the virus, NiV-G and NiV-F, mediate host-cell attachment and membrane fusion, respectively, and are targets of the host antibody response. Here, we provide a molecular basis for neutralization of NiV through antibody-mediated targeting of NiV-F. Structural characterization of a neutralizing antibody (nAb) in complex with trimeric prefusion NiV-F reveals an epitope at the membrane-distal domain III (DIII) of the molecule, a region that undergoes substantial refolding during host-cell entry. The epitope of this monoclonal antibody (mAb66) is primarily protein-specific and we observe that glycosylation at the periphery of the interface likely does not inhibit mAb66 binding to NiV-F. Further characterization reveals that a Hendra virus-F–specific nAb (mAb36) and many antibodies in an antihenipavirus-F polyclonal antibody mixture (pAb835) also target this region of the molecule. Integrated with previously reported paramyxovirus F−nAb structures, these data support a model whereby the membrane-distal region of the F protein is targeted by the antibody-mediated immune response across henipaviruses. Notably, our domain-specific sequence analysis reveals no evidence of selective pressure at this region of the molecule, suggestive that functional constraints prevent immune-driven sequence variation. Combined, our data reveal the membrane-distal region of NiV-F as a site of vulnerability on the NiV surface.
AB - Nipah virus (NiV) is a highly pathogenic paramyxovirus that causes frequent outbreaks of severe neurologic and respiratory disease in humans with high case fatality rates. The 2 glycoproteins displayed on the surface of the virus, NiV-G and NiV-F, mediate host-cell attachment and membrane fusion, respectively, and are targets of the host antibody response. Here, we provide a molecular basis for neutralization of NiV through antibody-mediated targeting of NiV-F. Structural characterization of a neutralizing antibody (nAb) in complex with trimeric prefusion NiV-F reveals an epitope at the membrane-distal domain III (DIII) of the molecule, a region that undergoes substantial refolding during host-cell entry. The epitope of this monoclonal antibody (mAb66) is primarily protein-specific and we observe that glycosylation at the periphery of the interface likely does not inhibit mAb66 binding to NiV-F. Further characterization reveals that a Hendra virus-F–specific nAb (mAb36) and many antibodies in an antihenipavirus-F polyclonal antibody mixture (pAb835) also target this region of the molecule. Integrated with previously reported paramyxovirus F−nAb structures, these data support a model whereby the membrane-distal region of the F protein is targeted by the antibody-mediated immune response across henipaviruses. Notably, our domain-specific sequence analysis reveals no evidence of selective pressure at this region of the molecule, suggestive that functional constraints prevent immune-driven sequence variation. Combined, our data reveal the membrane-distal region of NiV-F as a site of vulnerability on the NiV surface.
KW - Antibody response
KW - Glycoprotein
KW - Henipavirus
KW - Structure
KW - Viral fusion
UR - http://www.scopus.com/inward/record.url?scp=85076245439&partnerID=8YFLogxK
U2 - 10.1073/pnas.1912503116
DO - 10.1073/pnas.1912503116
M3 - Article
C2 - 31767754
AN - SCOPUS:85076245439
SN - 0027-8424
VL - 116
SP - 25057
EP - 25067
JO - Proceedings of the National Academy of Sciences of the United States of America
JF - Proceedings of the National Academy of Sciences of the United States of America
IS - 50
ER -